Weight loss peptides and medications
Losing weight is less about willpower than about biology: hunger hormones, blood sugar swings, and metabolism all push back. These articles look at the weight loss peptides and medications researchers study — how they work, what results have been measured, and what a realistic plan looks like alongside food and movement.
Nothing here is a shortcut or a guarantee. Medication is one tool, prescribed only when a licensed provider decides it fits your situation. Every article below is specific about what was measured and in whom.
81 articles on this topic
-
5 Percent Weight Loss Benefits: Study Numbers
Five percent can be a meaningful first milestone. Here's what studies measured in blood sugar, blood pressure, and sleep, and where the numbers stop being a useful prediction.
-
Semaglutide and Antidepressants: Can They Mix?
An antidepressant alone does not rule out semaglutide. The useful questions are how tablets are absorbed, how mood is doing, and what each medicine means for weight.
-
Should I Take Semaglutide? How a Provider Decides
A BMI of 32 can open the conversation. Medical history, current medicines and a workable follow-up plan determine where it goes.
-
When Was Rybelsus Approved? September 20, 2019
Rybelsus was approved on September 20, 2019. The FDA letter marked the moment a GLP-1 medicine moved from injection-only treatment into a daily tablet.
-
Does Semaglutide Cause Cancer? What Studies Show
Human studies have not established that semaglutide causes cancer. The thyroid warning remains, and lower cancer rates in some studies are not proof of prevention.
-
STEP 1 Trial Results: What the 14.9% Average Means
The 68-week semaglutide study found 14.9% average weight loss versus 2.4% with placebo. The details show who was studied, who stopped treatment and what happened later.
-
10 Questions to Ask Doctor About Tirzepatide
A tirzepatide visit is mostly about fit: the provider needs a clear picture of medical history, medicines, pregnancy plans, digestion, and upcoming procedures. These ten questions explain what matters and why.
-
SURMOUNT-1 Results: What the Trial Actually Found
SURMOUNT-1 followed 2,539 adults without diabetes for 72 weeks. Average weight change ranged from -15.0% to -20.9% with tirzepatide, compared with -3.1% with placebo.
-
15 Percent Weight Loss: What the Numbers Show
At 220 pounds, 15 percent is 33 pounds. Trials also measured waist, blood pressure, blood sugar, sleep, pain and physical function—but those group averages are not a personal forecast.
-
Who Discovered GLP-1? The Team Behind the Medicine
No single scientist discovered GLP-1. The answer is a chain of teams that found the gene, identified the working hormone, tested what it did, and designed medicines that lasted long enough to use.
-
Tirzepatide News Update: September 2026
The month's biggest change is narrow but important: Mounjaro gained a cardiovascular-risk indication for certain adults with type 2 diabetes. Here is what else changed—and what did not.
-
MOTS-c and Retatrutide: No Evidence for a Stack
No published study has tested MOTS-c and retatrutide together. Retatrutide cannot be compounded for patient care, while MOTS-c is a separate prescription discussion with much thinner human evidence.
-
MOTS-c for Weight Loss: Human Evidence Is Thin
Mouse studies are interesting, but no completed randomized trial shows that MOTS-c causes weight loss in people. Human studies so far mostly measure the peptide already in the body.
-
Semaglutide Meal Plan: A Simple Day Structure
A useful plan is flexible: smaller meals, protein early, fiber at a tolerable pace, and fluids across the day. This sample day uses portion ranges rather than a calorie rule.
-
Compounded Semaglutide Side Effects: What Changes?
Most compounded semaglutide side effects come from semaglutide itself. Compounding can add separate risks involving concentration, added ingredients, ingredient form, sterility, and labeling.
-
Semaglutide Pronunciation: How to Say It
Semaglutide is pronounced sem-a-GLOO-tide. The middle is easier once you know where the stress goes and why several related medicine names share the same ending.
-
Tesamorelin vs Tirzepatide: Which Fits Which Goal?
Tesamorelin and tirzepatide can both change fat-related measures, but they answer different clinical questions. One has narrow evidence for deep abdominal fat in adults with HIV lipodystrophy; the other was studied for total body weight.
-
Semaglutide Type 1 Diabetes: Guidance Has Limits
New 2026 guidance treats GLP-1 therapy as a possible obesity tool for some adults with type 1 diabetes, not as a replacement for insulin. The evidence is promising but small, and semaglutide is not approved to treat type 1 diabetes.
-
Tirzepatide Meal Plan: Small Meals, Protein First
A useful tirzepatide meal plan is smaller and steadier: protein first, produce and fiber as tolerated, and fluids between meals. It should bend around appetite and side effects, not force a calorie target.
-
Semaglutide Before and After: An Honest Timeline
The first month is usually an adjustment period, month six is still part of the active curve, and a plateau often comes much later. Photos cannot show the treatment, timing, or follow-up behind a change.
Page 1 of 5 · 81 articles